Equities

Spago Nanomedical AB (publ)

Spago Nanomedical AB (publ)

Actions
  • Price (SEK)0.341
  • Today's Change-0.017 / -4.75%
  • Shares traded136.41k
  • 1 Year change-55.15%
  • Beta1.9870
Data delayed at least 15 minutes, as of May 03 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Spago Nanomedical publ AB, formerly Spago Imaging publ AB, is a Sweden-based biotechnology company. It specialized in the areas of contrast agents and nanoscale life science research. The Company is involved in three projects: Spago Pix, a nanomaterial developed for use as a cancer selective contrast agent for Magnetic Resonance Imaging (MRI); the therapeutic project Tumorad, using nanoparticles loaded with radionuclides for selective treatment of cancers, which are unsuitable for surgery or external radiation; and Archaea Platin, aimed at delivering of chemotherapeutic substance cisplatin selectively to tumors in order to reduce side effects on healthy tissue. The Company's technology comprises a technology platform IonXgel, which is a nano-sized biocompatible material consisting of polar polymers; a protein-based drug delivery platform, ProtRc; and 3PEG, a platform which enables attachment of polyethylene glycol (PEG) derivatives to small molecules (PEGylation).

  • Revenue in SEK (TTM)1.20m
  • Net income in SEK-42.22m
  • Incorporated1999
  • Employees13.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
PCI Biotech Holding ASA2.97m-20.20m59.32m7.00--1.53--19.95-0.5443-0.54430.08011.050.0556--0.6848427,142.80-37.78-36.44-41.97-40.14-----679.43-1,055.43----0.0081---37.05-20.7863.13------
Orphazyme A/S0.00-40.68m60.50m1.00--2.72-----737.75-737.750.00403.340.00----0.00-68.42-76.08-94.18-105.34------------0.00------32.00------
Coegin Pharma AB0.00-27.98m61.23m----4.70-----2.67-2.670.000.64040.00-------125.24-122.02-201.53-154.70-----------170.65--------20.60------
Double Bond Phrmcutcl Intrntnl AB (publ)1.37m-17.34m63.85m10.00--11.37--46.59-0.1837-0.18370.01360.05560.1016--18.59137,033.00-128.49-80.90-198.98-106.45-241.22-686.41-1,265.24-1,360.03---217.550.00--10.25135.07-14.36------
Chosa Oncology AB73.00k-23.94m64.74m----3.72--886.91-0.3524-0.35240.00130.26840.003--0.013---96.68-51.96-178.66-61.92-----32,798.63-708.47---97.97-----98.21--28.33------
Abera Bioscience AB0.00-16.72m69.09m----11.51-----1.24-1.240.000.3910.00-------115.63-79.43-149.06-96.11--------------------13.73------
SoftOx Solutions AS6.94m-41.85m70.31m--------10.13-1.98-1.980.3286-0.01270.081--1.60---48.81-50.83-82.20-64.58-----602.91-646.670.1745-3.45-----1.8810.0640.85--39.43--
Combigene AB5.54m-35.67m73.86m8.00--0.6342--13.32-1.80-1.800.285.880.0398--2.63693,015.00-25.58-13.00-26.56-14.58-----643.32-58.77----0.00---79.23268.58-479.27---24.02--
ViroGates A/S8.72m-18.89m74.31m10.00--2.80--8.52-6.12-6.121.612.640.26530.26543.15558,300.00-57.47-46.58-63.01-52.0978.8377.91-216.66-238.018.56-23.890.2376---45.0110.98-25.40------
ExpreS2ion Biotech Holding AB8.80m-95.99m74.74m28.00--1.23--8.49-2.12-2.120.18951.190.0832--9.91---90.72-64.80-113.72-77.46-109.74-1.94-1,090.91-532.25----0.0045--43.07-0.156119.07--19.90--
Spago Nanomedical AB (publ)1.20m-42.22m76.63m13.00--1.81--63.70-0.3818-0.38180.01150.18820.0093--5.7492,538.46-32.61-20.19-35.38-20.97247.55---3,509.81-4,853.45--------14.14---7.72------
Prolight Diagnostics AB (publ)0.00-27.75m77.97m----0.2246-----0.0984-0.09840.000.6946-----------------------------------------13.84--
Immunovia AB (publ)1.21m-260.73m84.33m11.00--1.93--69.58-6.06-6.060.02760.96480.007558.2314.96110,181.80-160.93-41.33-194.89-44.24-5,523.76-7,553.76-21,512.13-20,879.292.03--0.1675--37.5536.48-84.09---50.93--
Bioextrax AB publ2.06m-21.51m86.31m----3.60--41.96-0.8026-0.80260.07690.69680.0681--124.67---71.18-86.39-82.24-110.8434.95---1,045.55-2,119.90--------420.5124.40-15.21--56.86--
Dextech Medical AB0.00-4.57m92.06m1.00--2.85-----0.2473-0.24730.001.750.00-------13.04-28.96-13.21-29.94------------0.00------12.89--0.412--
Ziccum AB3.75m-21.41m92.23m8.00--9.69--24.62-1.54-1.540.27010.61910.1553--2.01468,375.00-88.74-68.51-109.73-76.47-----571.44-2,598.03----0.0908----75.2025.62---13.45--
Data as of May 03 2024. Currency figures normalised to Spago Nanomedical AB (publ)'s reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.